In TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy), which evaluated patients with T2DM, predialysis chronic kidney disease (CKD), and anemia, the addition of NT-proBNP and troponin T to a multivariate model was associated with a net improvement of 17.8% in predicting CV outcomes [68]. Here, NPPB is linked to type 2 diabetes mellitus.